BioMed Research International
Volume 2019 (2019), Article ID 3891535, 6 pages
https://doi.org/10.1155/2019/3891535

Research Article

Peroxynitrite and 4-Hydroxynonenal Inactivate Breast Cancer Resistance Protein/ABCG2

Svetlana Verenich and Phillip M. Gerk

Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, P.O. Box 980533, Richmond, VA 23298-0533, USA

Correspondence should be addressed to Phillip M. Gerk; pmgerk@vcu.edu

Received 3 October 2018; Revised 19 December 2018; Accepted 26 December 2018; Published 21 January 2019

Academic Editor: Paul M. Tulkens

Copyright © 2019 Svetlana Verenich and Phillip M. Gerk. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Oxidative stress may arise from a variety of pathologies and results in the formation of toxic and reactive chemical species. Extensive research has been done to establish mechanisms of formation and cytotoxic effects of a number of different products of oxidation stress including peroxynitrite (PN) and 4-hydroxynonenal (4HNE). However, relatively few studies have investigated their effects on ATP-binding cassette (ABC) transporters. The objective of this investigation was to determine the effects of PN and 4HNE on BCRP/ABCG2. To eliminate the effect of metabolic enzymes, the experiments were carried out with inside-out Sf9 membrane vesicles overexpressing BCRP/ABCG2 using riboflavin as a substrate. The experiments revealed that PN produced IC₅₀ of about 31.2 ± 2.7 μM, based upon initial concentrations. The IC₅₀ for 4HNE was estimated to be 92 ± 1.4 μM. Preincubation of membrane vesicles with either PN or 4HNE caused the maximal rate of transport () to drop drastically, up to 19 times, with no or much smaller effect on . Thus, PN and 4NE can inhibit BCRP transport activity.

1. Introduction

Oxidative stress is a frequent complication of various disease conditions such as Alzheimer and Parkinson’s diseases [1, 2], atherosclerosis [3], HIV [4], preeclampsia [5], rheumatoid arthritis [6], and diabetes [7] including gestational diabetes [8]. Different molecules associated with oxidative stress are involved in the development of pathogenesis; however peroxynitrite (PN) and 4-hydroxynonenal (4HNE) are the most studied. The former is a reaction product of superoxide and nitric oxide, while 4HNE is a product of lipid peroxidation of polyunsaturated fatty acids [9]. Both of them are implicated in damage, adduction, or inhibition of synthesis of DNA or RNA, cell apoptosis or necrosis, mitochondrial dysfunction, and lipid peroxidation [10, 11]. Typically 4HNE actively forms adducts with thiol-containing amino acids or substances such as glutathione and cysteine and with lysine, histidine residues of protein; PN, on the other hand, reacts with methionine and cysteine, as well as residues of tyrosine and tryptophan by oxidizing or nitrating them [9, 12]. All of the above indicate that PN and 4HNE are capable of damaging or disrupting the functionality of proteins. Thus, it was reported that PN could inhibit Na-K-, Ca²⁺-, and Mg²⁺-ATPases [13, 14]. However, the effect of PN and 4HNE on ATP-binding cassette (ABC) transporters has not been thoroughly investigated.

ABC transporters modulate the movements of nutrient or xenobiotics across the membrane by utilizing the energy from ATP. P-glycoprotein (ABCB1) and BCRP (breast cancer resistance protein) [15] are an important determinant of drug absorption and tissue penetration. So far, only Soszyński and Bartosz [16] have reported that peroxynitrite showed an inhibition of transport of S-conjugates modulated by ABCC1 (MRP1).

The purpose of this study was to demonstrate if 4HNE and PN can inhibit the transport of riboflavin mediated by BCRP/ABCG2 and identify half maximal inhibitory concentration (IC₅₀) for both PN and 4HNE. To eliminate the interference of metabolism, the experiments were performed with Sf9 membrane vesicles overexpressing BCRP. Thus, this investigation provides evidence that both 4HNE and PN inactivate BCRP, with peroxynitrite being more potent.

2. Materials and Methods

2.1. Materials

Riboflavin was obtained from MP Biomedicals, Inc. (Solon, OH). Peroxynitrite (PN) and 4-hydroxynonenal (4HNE) were purchased from Cayman Chemical (Ann Arbor, MI) and stored at –80°C. The concentration of PN was determined by diluting in ice-cold 0.3N NaOH, determining the absorbance at 302nm and calculating the concentration based on the extinction coefficient for peroxynitrite (1670 M⁻¹cm⁻¹). All other reagents and solvents were obtained from Sigma-Aldrich (St. Louis, MO).

2.2. Sf9 Membrane Vesicle Preparation and Transport Study

Inside-out Sf9 membrane vesicles overexpressing human BCRP or empty vector (i.e., lacking ABC transporters) were prepared as previously described [17, 18]. Briefly, a suspension of Sf9 cells was infected with titered viral stocks of BCRP or empty vector (EV) at a multiplicity of infection of 4. After 48 hours, Sf9 cells were harvested, lysed, and homogenized; then their membranes were isolated by fractionation over 38% sucrose. Isolated membranes were vesiculated, snap frozen in liquid nitrogen, and stored at – 80°C. The membrane protein concentrations were determined by the modified Lowry protein assay with bovine serum albumin used as a standard. [19]

Transport experiments were carried out as described in Gerk et al. [20] with small modifications in the procedure. The final buffer concentrations were tris-HCL 10mM (pH 7.4), sucrose 250mM, 5 mM ATP or AMP, 10 mM phosphocreatine, 100 μg/ml creatine phosphokinase, 10 mM MgCl₂, riboflavin in deionized water, or dimethyl sulfoxide (0.5%) with or without reduced glutathione (1mM). For osmotic sensitivity experiments, sucrose concentrations from 250mM to 1M were used. For experiments with PN, tris-HCl was replaced with triethanolamine HCl 10mM (pH 7.4). ATP-dependent transport of riboflavin was conducted in 96-well PCR plates with a reaction volume of 60 μl incubated at 37°C between 2 and 60 min. Transport activity was stopped by transferring 50 μl to a 96-well filter plate with prewetted 0.45 μm PVDF filters (Millipore Corporation, Bedford, MA) and by quick washing under vacuum with ice-cold stop buffer (3 x 200 μl) to harvest membrane vesicles. To elute riboflavin, 100 μl of water/dimethyl sulfoxide mixture (3:1) was added to the filter plate and centrifuged at room temperature for 8 min at 350 . The filtrate was collected in a black-sided clear bottom 96-well plate (Costar 3631, Corning Inc., Corning, NY). Riboflavin was quantitated using a microplate reader Synergy™ 2 (BioTek Instruments, Inc., Winooski, VT) with excitation and emission wavelengths of 450 and 528 nm, respectively. The ATP-dependent transport of riboflavin was estimated as a difference between the values obtained in the presence of ATP or AMP. For the experiments with PN and 4HNE, the membrane vesicles were preincubated with PN or 4HNE at 37°C for 30 min prior to the transport experiments.

2.3. Data Analysis for Transport Kinetics

Kinetic parameters were estimated from curve fitting using GraphPad Prism for Windows (version 5, GraphPad Software Inc., San Diego, CA) by means of unweighted nonlinear regression using the Hill equation and the sigmoidal dose-response equation.

All data values were expressed as a mean of 3 or 4 independent determinations. The effect of PN and 4HNE on ATP-dependent transport of riboflavin was compared by analysis of variance (one-way ANOVA) followed by Dunnett’s posttest or unpaired t-test. A value of p < 0.05 (2-sided) was considered statistically significant. Goodness of fit of different models was compared using Akaike information criterion (AIC).

3. Results

In this work we investigated ATP-dependent uptake of riboflavin (vitamin B₂) into inside-out Sf9 membrane vesicles overexpressing BCRP/ABCG2. Thus, Figure 1(a) depicts that, in the presence of ATP, the membrane vesicles showed a time-dependent transport of riboflavin, whereas EV membrane vesicles demonstrated minimal transport, which was <20% of the total transport in BCRP membrane vesicles. As can be seen, riboflavin transport was linear for 5 min. Therefore, all the following BCRP-mediated experiments were carried out for 5 min. Figure 1(b) shows that ATP-dependent riboflavin transport occurs in an osmotically sensitive space (using sucrose to modify osmolarity), with negligible binding.

(a)

(b)

Figure 1: BCRP-mediated uptake of riboflavin into Sf9 inside-out membrane vesicles. Each data point represents mean ± SD from 3-4 determinations, expressed as pmol riboflavin/mg protein. (a) Time course of riboflavin (10 μM) uptake into Sf9 membrane vesicles overexpressing BCRP/ABCG2 (filled circles) and EV vesicles (open circles). Protein amount is 10 μg; (b) effect of sucrose (osmolarity) on ATP-dependent uptake of riboflavin (10 μM) into Sf9 vesicles. The transport was determined after 5 min in the presence of varying sucrose concentrations (250-1000μM).

3.1. Effect of 4-Hydroxynonenal (4HNE)

The kinetic parameters for BCRP-mediated transport of riboflavin were assessed by fitting the Hill equation to the data from Figure 2(a). Due to the limited solubility of riboflavin, complete saturation of ABCG2 was not possible to achieve. The maximum concentration of riboflavin tested was 300 μM. The estimates of and were 296 ± 71 μM and 1407 ± 193 pmol/mg protein/min, respectively, with Hill slope of 1.0. The results of riboflavin uptake in the presence of 200 μM of 4HNE, a product of lipid peroxidation, are also shown in Figure 2(a). The kinetic parameters estimated with Hill equation are 168 ± 32 μM and 342 ± 43 pmol/min/mg for and , respectively, with a Hill coefficient of 1.6 (suggesting modest positive cooperativity). Thus, was reduced 4-fold, whereas remained unchanged (unpaired t-test, p > 0.05). These parameters indicate that 4HNE is capable of inactivating BCRP/ABCG2 transport activity. The inhibitory effect of 4HNE (0 to 200 μM) on riboflavin uptake is illustrated in Figure 2(b). The maximal inhibitory concentration (IC₅₀) was estimated to be 92 ± 1.4 μM.

(a)

(b)

Figure 2: Effect of 4-hydroxynonenal (4HNE) on the transport of riboflavin into Sf9-BCRP/ABCG2 membrane vesicles, expressed as pmol riboflavin/mg protein/min. Data are mean ± SD from 3-4 determinations. (a) BCRP-mediated transport of riboflavin in the presence of 200 μM of 4HNE (filled circles) vs. control (open symbols); (b) inhibition of riboflavin uptake by 4-hydroxynonenal (4HNE).

3.2. Effect of Peroxynitrite (PN)

The kinetic parameters for ATP-dependent riboflavin transport in the presence of an initial concentration of 50 μM of PN were determined by fitting with the Hill equation. Because PN anion is highly unstable at physiological pH, it is supplied in strongly alkaline solutions. Therefore to maintain the reaction buffer at the desired pH of 7.4, a buffer containing triethanolamine HCl (pKa ~ 7.6) instead of tris-HCl was utilized. Because of the changes in buffer constituent, additional experiments were carried out without PN to account for the effects of sodium hydroxide and triethanolamine. The kinetic parameters from these experiments were then compared to those obtained in the presence of 50 μM of PN. The results are shown in Figure 3(a). In the absence of PN, and were estimated to be 685 ± 167.2 μM and 2663 ± 485.9 pmol/min/mg, respectively, with Hill slope of 1.0. This compares to of 90 ± 39.2 μM and of 141 ± 23.4 pmol/min/mg, obtained with 50 μM PN, with Hill slope of 1.0. Thus the presence of 50 μM PN drastically reduced and Km 19- and 7.5-fold, respectively, suggesting a mixed type of inhibition.

(a)

(b)

Figure 3: Effect of peroxynitrite (PN) on uptake of riboflavin into Sf9-BCRP/ABCG2 membrane vesicles, expressed as pmol riboflavin/mg protein/min. Data are mean ± SD from 3-4 determinations. (a) BCRP-mediated transport of riboflavin in the presence of 50 μM of PN (filled symbols) vs. control (open symbols); (b) inhibition of riboflavin uptake by peroxynitrite (PN).

The effect of PN on the riboflavin uptake by Sf9 membrane vesicles was tested only at initial PN concentrations of up to 100 μM, since at this concentration almost complete inactivation of BCRP was observed. The inhibition curve for BCRP-mediated riboflavin transport is shown in Figure 3(b). IC₅₀ was estimated to be 31 ± 2.7 μM indicating that PN is a slightly more potent inhibitor of BCRP/ABCG2 than 4HNE.

4. Discussion

It has been demonstrated earlier that riboflavin is a substrate of BCRP [21, 22] and its accumulation in membrane vesicles can be easily measured due to its native fluorescence. In this assay, we made use of this property to rapidly determine BCRP transport activity in a 96-well format with quantitation using a fluorescence plate reader. Previously, a high-speed transport activity assay for BCRP was reported using a 96-well format, with ³H-methotrexate as a substrate [23]. However, the present assay was more rapid and less expensive and has less environmental impact than one using radioactivity.

BCRP is expressed at the apical surface of the placental syncytiotrophoblast, where it may be exposed to peroxynitrite and 4-hydroxynonenal released from neutrophils through physiologic and pathophysiologic mechanisms. In the maternal blood circulating through the placenta, activated neutrophils release superoxide as well as lipid peroxides [24]. Superoxide combines with nitric oxide, which is present as an important vasodilator, to form peroxynitrite. Peroxynitrite is highly reactive, particularly forming nitrotyrosine adducts on nearby proteins. Also, lipid peroxidation initiated by the activated neutrophils will result in the formation of reactive aldehydes such as 4HNE and malondialdehyde [25].

4HNE has three main functional groups: an aldehyde, a carbon-carbon double bond, and a hydroxyl group, which can react alone or in sequence of reactions [10]. Due to its lipophilic nature 4HNE has a tendency to accumulate within the lipid bilayer at the site of lipid peroxidation and reach concentrations up to 4.5 mM [26]. Thus, the IC₅₀ we reported (92μM) could be observed in vivo. However, at concentrations ranging from 1 to 20 μM, 4HNE can already inhibit DNA and protein synthesis, and cytotoxicity is observed at ≥ 100 μM [10]. The inhibition of BCRP/ABCG2 activity occurs slightly slower and concurrently with inhibition of other vital cell processes. One must note however that in the present experiments 4HNE was added to the aqueous buffer. This would require some time for 4HNE to diffuse into the bilayer, whereas in vivo 4HNE is usually generated within lipid bilayers. Thus, the IC₅₀ values obtained in this study could be overestimated due to possible reactions of 4HNE with other biomolecules before reaching a target transporter [26]. The increase in the Hill coefficient due to 4HNE is not readily explained and would require further studies but could be due to a denaturation of the transporter protein or its lipid environment [27]. Notably, the kinetic parameters in the control experiments differed significantly. This may be due to the change in buffer from tris-HCl to triethanolamine-HCl; furthermore, it may be a result of the 30-minute preincubation step prior to the transport experiments.

Although peroxynitrite anion is relatively short-lived, it not only causes lipid peroxidation but also diffuses inside the lipid bilayer and oxidizes or nitrates integral membrane proteins. Under physiological conditions, PN concentrations can be as high as 50 to 100 μM, but its steady-state concentration is usually in nanomolar range, which can be sustained for a long period of time. [11] Thus, a tissue can have a very high cumulative exposure to PN. Grover et al. [28], for instance, have reported that Ca²⁺ pumps (SERCA) can be inhibited by 50% at PN concentrations of about 50 μM (in vitro). Hence IC₅₀ of PN obtained in this study (31μM) can be easily observed under physiological conditions, with inactivation of BCRP.

5. Conclusion

In conclusion, the present study was conducted to investigate the effect and potency of peroxynitrite (PN) and 4-hydroxynonenal (4HNE), a product of lipid peroxidation, on the activity of BCRP/ABCG2. This investigation revealed that PN (IC₅₀ = 31 μM) and 4HNE (IC₅₀ = 92 μM) inactivate BCRP/ABCG2 at biologically relevant concentrations. Since the formation of excess PN and 4HNE often takes place during different stages of various disease conditions, PN and 4HNE are capable of decreasing the activity of ABC transporters, which may affect drug disposition.

Abbreviations

4HNE: | 4-Hydroxynonenal
ABC: | ATP-binding cassette
BCRP: | Breast cancer resistance protein/ABCG2
OSP: | Oxidative stress products
PN: | Peroxynitrite.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Disclosure

This work was part of an M.S. degree thesis submitted by Svetlana Verenich to Virginia Commonwealth University.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgments

The authors gratefully acknowledge funding support from the Thomas F. and Kate Miller Jeffress Trust, the American Association of Colleges of Pharmacy New Investigator Program, the VCU School of Pharmacy, and the VCU Graduate School. They thank Dr. Scott Walsh for helpful discussions on oxidative stress mechanisms.

References

M. Zhu, F. Gu, J. Shi, J. Hu, Y. Hu, and Z. Zhao, “Increased oxidative stress and astrogliosis responses in conditional double-knockout mice of Alzheimer-like presenilin-1 and presenilin-2,” Free Radical Biology & Medicine, vol. 45, no. 10, pp. 1493–1499, 2008.

M. Ebadi and S. K. Sharma, “Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease,” Antioxidants & Redox Signaling, vol. 5, no. 3, pp. 319–335, 2003.

G. M. Chisolm and D. Steinberg, “The oxidative modification hypothesis of atherogenesis: an overview,” Free Radical Biology & Medicine, vol. 28, no. 12, pp. 1815–1826, 2000.

L. Gil, D. Pérez, R. Tápanes, J. Pérez, and T. Grune, “Does mitochondrial dysfunction during antiretroviral therapy in human immunodeficiency virus infection suggest antioxidant supplementation as a beneficial option?” Redox Report, vol. 10, no. 3, pp. 113–119, 2005.

C. A. Hubel, “Oxidative stress in the pathogenesis of preeclampsia,” Proceedings of the Society for Experimental Biology and Medicine, vol. 222, no. 3, pp. 222–235, 1999.

C. Kunsch, J. Sikorski, and C. Sundell, “Oxidative Stress and the Use of Antioxidants for the Treatment of Rheumatoid Arthritis,” Current Medicinal Chemistry-Immunology, Endocrine & Metabolic Agents, vol. 5, no. 3, pp. 249–258, 2005.

C. Figueroa-Romero, M. Sadidi, and E. L. Feldman, “Mechanisms of disease: the oxidative stress theory of diabetic neuropathy,” Reviews in Endocrine & Metabolic Disorders, vol. 9, no. 4, pp. 301–314, 2008.

M. T. Coughlan, P. P. Vervaart, M. Permezel, H. M. Georgiou, and G. E. Rice, “Altered placental oxidative stress status in gestational diabetes mellitus,” Placenta, vol. 25, no. 1, pp. 78–84, 2004.

B. S. Berlett and E. R. Stadtman, “Protein oxidation in aging, disease, and oxidative stress,” The Journal of Biological Chemistry, vol. 272, no. 33, pp. 20313–20316, 1997.

H. Esterbauer, R. J. Schaur, and H. Zollner, “Chemistry and biochemistry of 4-hyroxynonenal, malonaldehyde and related aldehydes,” Free Radical Biology & Medicine, vol. 11, no. 1, pp. 81–128, 1991.

C. Szabó, H. Ischiropoulos, and R. Radi, “Peroxynitrite: biochemistry, pathophysiology and development of therapeutics,” Nature Reviews Drug Discovery, vol. 6, no. 8, pp. 662–680, 2007.

E. Shacter, “Quantification and significance of protein oxidation in biological samples,” Drug Metabolism Reviews, vol. 32, no. 3-4, pp. 307–326, 2000.

M. S. Reifenberger, K. L. Arnett, C. Gatto, and M. A. Milanick, “The reactive nitrogen species peroxynitrite is a potent inhibitor of renal Na-K-ATPase activity,” American Journal of Physiology-Renal Physiology, vol. 295, no. 4, pp. F1191–F1198, 2008.

M. Soszyński and G. Bartosz, “Effect of peroxynitrite on erythrocytes,” Biochimica et Biophysica Acta (BBA) - General Subjects, vol. 1291, no. 2, pp. 107–114, 1996.

A. H. Schinkel and J. W. Jonker, “Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview,” Advanced Drug Delivery Reviews, vol. 55, no. 1, pp. 3–29, 2003.

M. Soszyński and G. Bartosz, “Peroxynitrite inhibits glutathione S-conjugate transport,” Biochimica et Biophysica Acta (BBA) - Biomembranes, vol. 1325, no. 1, pp. 135–141, 1997.

S. S. Vaidya and P. M. Gerk, “Lack of interaction between tauroursodeoxycholate and ATP-binding cassette transporter isoform G2 (ABCG2),” Molecular Pharmaceutics, vol. 3, no. 3, pp. 303–306, 2006.

K. Ito, H. Suzuki, and Y. Sugiyama, “Single amino acid substitution of rat MRP2 results in acquired transport activity for taurocholate,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 281, no. 4, pp. G1034–G1043, 2001.

O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, “Protein measurement with the Folin phenol reagent,” The Journal of Biological Chemistry, vol. 193, pp. 265–275, 1951.

P. M. Gerk and M. Vore, “Multidrug resistance proteins and hepatic transport of endo- and xenobiotics,” in Drug Metabolism and Transport: Molecular Methods and Mechanisms, L. H. Lash, Ed., pp. 273–289, Humana Press, Totowa, NJ, 2004.

I. Ifergan, V. Goler-Baron, and Y. G. Assaraf, “Riboflavin concentration within ABCG2-rich extracellular vesicles is a novel marker for multidrug resistance in malignant cells,” Biochemical and Biophysical Research Communications, vol. 380, no. 1, pp. 5–10, 2009.

A. E. Van Herwaarden, E. Wagenaar, G. Merino et al., “Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk,” Molecular and Cellular Biology, vol. 27, no. 4, pp. 1247–1253, 2007.

H. Saito, H. Hirano, H. Nakagawa et al., “A new strategy of high-speed screening and quantitative structure-activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions,” The Journal of Pharmacology and Experimental Therapeutics, vol. 317, no. 3, pp. 1114–1124, 2006.

J. E. Vaughan, S. W. Walsh, and G. D. Ford, “Thromboxane mediates neutrophil superoxide production in pregnancy,” American Journal of Obstetrics & Gynecology, vol. 195, no. 5, pp. 1415–1420, 2006.

L. Myatt and X. Cui, “Oxidative stress in the placenta,” Histochemistry and Cell Biology, vol. 122, no. 4, pp. 369–382, 2004.

J. F. Koster, R. G. Slee, A. Montfoort, J. Lang, and H. Esterbauer, “Comparison of the inactivation of microsomal glucose-6-phosphatase by in situ lipid peroxidation-derived 4-hydroxynonenal and exogenous 4-hydroxynonenal,” Free Radical Research, vol. 1, no. 4, pp. 273–287, 1986.

R. A. Copeland, Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists, John Wiley & Sons, Hoboken, NJ, 2nd edition, 2013.

A. K. Grover, C.-Y. Kwan, and S. E. Samson, “Effects of peroxynitrite on sarco/endoplasmic reticulum Ca2+ pump isoforms SERCA2b and SERCA3a,” American Journal of Physiology-Cell Physiology, vol. 285, no. 6, pp. C1537–C1543, 2003.